##  [Supporting IND Approval and Regulatory Strategy for a COVID-19 Recombinant Protein Vaccine in China](/index%2ephp/success-stories/supporting-ind-approval-and-regulatory-strategy-for-a-covid-19-recombinant-protein-vaccine-in-china) 

# Supporting IND Approval and Regulatory Strategy for a COVID-19 Recombinant Protein Vaccine in China

Delivering comprehensive China Regulatory Affairs consulting, IND application support, Regulatory strategy, and NMPA compliance services for a COVID-19 recombinant protein vaccine while enabling successful Investigational New Drug (IND) approval and supporting accelerated clinical development in China.





![]()









### Successful



IND approval for a COVID-19 recombinant protein vaccine in China







### Accelerated



preparation and submission of IND documentation







### Effective



management of Regulatory queries and Health Authority interactions













![Client Overview]()



![Icon]()  

## Client Overview



A China-based biopharmaceutical company developing a COVID-19 recombinant protein vaccine required expert Regulatory Affairs and Regulatory strategy support to secure IND approval and advance the product into clinical development. The client sought assistance with navigating China's evolving vaccine Regulatory landscape, preparing IND submission documentation, addressing technical Regulatory requirements, and managing interactions with the National Medical Products Administration (NMPA).











![Background Icon]()  

## Background



As part of its vaccine development program, the client planned to submit an Investigational New Drug (IND) application for a COVID-19 recombinant protein vaccine in China. Given the urgent public health need and the rapidly evolving Regulatory environment for COVID-19 vaccines, the company required a robust Regulatory strategy to support timely IND approval and clinical trial initiation.

The client needed an experienced Regulatory partner capable of providing strategic guidance on NMPA requirements, clinical trial applications, vaccine development regulations, and submission planning to ensure a successful Regulatory outcome.





![Scope Icon]()  

## Services in Scope



![]()

IND Application Strategy and Planning



![]()

Regulatory Gap Analysis and Documentation Review



![]()

NMPA Consultation and Regulatory Communication



![]()

Vaccine Development Regulatory Support



![]()

Clinical Trial Application Guidance



![]()

CMC Documentation and Regulatory Review



![]()

Health Authority Query Management



![]()

Regulatory Compliance and Submission Support















![Challenge]()



![Challenge]()

## Challenge



![Challenge]()

**Accelerated Vaccine Development Timelines** The client needed to progress vaccine development rapidly while maintaining compliance with China's Regulatory requirements and clinical trial expectations.





![Challenge]()

**Evolving COVID-19 Regulatory Requirements** Frequent updates to vaccine-related Regulatory guidance required continuous monitoring and alignment with NMPA expectations.





![Challenge]()

**Complex Technical and CMC Requirements** The IND application required comprehensive technical documentation, including quality, nonclinical, and CMC data, to support vaccine safety and efficacy evaluations.





![Challenge]()

**Regulatory Strategy for IND Approval** The client required a clear Regulatory pathway to facilitate IND approval and support timely clinical development milestones.















![Challenge]()

## Solution



1

![Challenge]()

##### Regulatory Strategy Development

Provided strategic guidance on IND submission planning, Regulatory expectations, and vaccine development pathways to support successful approval.





2

![Challenge]()

##### NMPA Consultation Support

Facilitated Regulatory interactions and consultations with the NMPA to clarify requirements and align development activities with Health Authority expectations.





3

![Challenge]()

##### Documentation Review and Gap Assessment

Conducted comprehensive reviews of technical, clinical, and CMC documentation to identify gaps and strengthen submission readiness.





4

![Challenge]()

##### IND Submission Support

Supported preparation, compilation, and review of IND application materials to ensure compliance with NMPA requirements and vaccine-specific guidance.





5

![Challenge]()

##### Regulatory Query Management

Provided timely support for Health Authority communications and Regulatory questions to facilitate efficient review and approval activities.











![Challenge]()

## Impact



Freyr's support enabled the client to successfully obtain IND approval for a COVID-19 recombinant protein vaccine while strengthening Regulatory readiness and accelerating clinical development activities.



![Challenge]()

##### Regulatory Excellence 

- Achieved successful IND approval in China
- Ensured compliance with NMPA vaccine development requirements
- Strengthened submission quality and Regulatory documentation
- Improved alignment with evolving COVID-19 Regulatory guidance





![Challenge]()

##### Faster Submission Execution 

- Accelerated IND preparation and approval activities
- Supported the timely initiation of clinical development programs
- Reduced Regulatory uncertainty through proactive strategy development





![Challenge]()

##### Operational Efficiency 

- Streamlined Regulatory planning and submission management
- Improved coordination between development and Regulatory teams
- Enhanced visibility into key Regulatory milestones and timelines





![Challenge]()

##### Business Value 

- Enabled progression of an innovative COVID-19 vaccine candidate into clinical trials
- Strengthened the client's vaccine development strategy in China
- Supported faster Regulatory decision-making and market readiness
- Enhanced competitiveness in the rapidly evolving vaccine landscape